世界のサラセミア市場の規模、シェア、トレンド分析レポート – 業界の概要と2032年までの予測

Get Exclusive Sample PDF of this Report Here

サラセミア市場分析

遺伝子治療、診断技術、治療法の進歩により、サラセミア市場は著しい成長を遂げています。最近の最も注目すべき進歩の 1 つは、ヘモグロビン生成遺伝子の変異を修正することでサラセミアの潜在的な治療法を提供する CRISPR-Cas9 などの遺伝子編集技術です。これらの技術は臨床試験でテストされており、一部では有望な結果が示されており、より個別化された効果的な治療への道を開いています。

もう一つの画期的な技術はCAR-T細胞療法であり、特に鉄過剰症の患者におけるサラセミア関連の合併症の管理における可能性に注目が集まっています。

さらに、高度な遺伝子スクリーニング技術や液体生検技術の導入により非侵襲性の診断ツールが進化し、早期かつより正確な検出が可能になり、誤診の負担が軽減されました。

治療面では、サラセミア遺伝子治療により定期的な輸血の必要性が大幅に減り、患者の生活の質が向上することが期待されています。これらの技術革新により、治療効果の向上と個別化アプローチによって市場は大幅に成長すると予測されています。

サラセミア市場規模

世界のサラセミア市場規模は、2024年に9億8,600万米ドルと評価され、2025年から2032年の予測期間中に16.00%のCAGRで成長し、2032年までに32億3,252万米ドルに達すると予測されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Researchがまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

サラセミア市場の動向

「遺伝子治療の進歩」

サラセミア市場における重要なトレンドの 1 つは、遺伝子治療の開発と承認です。これらの治療は、症状を管理するだけでなく、サラセミアの根本原因に対処することで長期的な解決策を提供することを目指しています。ベータサラセミアの遺伝子治療である Zynteglo の承認は、この分野における画期的な出来事でした。この治療では、機能的なヘモグロビンを生成するように改変された患者自身の幹細胞を使用します。これにより、輸血の必要性が大幅に軽減または排除され、重度のサラセミア患者に希望がもたらされます。遺伝子治療への注目が高まることで、治療に革命が起こり、市場の成長が促進され、多額の投資が引き寄せられるでしょう。

レポートの範囲とサラセミア市場のセグメンテーション

Get Exclusive Sample PDF of this Report Here

サラセミア市場の定義

サラセミアは、赤血球内の酸素を運ぶタンパク質であるヘモグロビンの異常な生成を特徴とする遺伝性の血液疾患です。このため、貧血、疲労、衰弱、その他の合併症が起こります。ヘモグロビン分子のどの部分が影響を受けているかによって、アルファサラセミアとベータサラセミアの 2 つの主なタイプがあります。サラセミアは両親から遺伝し、重症度はさまざまです。重症の場合は定期的な輸血が必要ですが、軽症の場合は介入が少なくて済む場合があります。早期診断と治療は症状の管理に役立ちますが、現時点では万能な治療法はありません。

サラセミア市場の動向

ドライバー

• サラセミアの罹患率の増加

特にインド、中東、地中海などの地域でのサラセミアの罹患率の上昇は、市場の大きな原動力となっています。サラセミアはインドなどの国で風土病となっており、インドでは毎年約 10,000 人の子供が重症サラセミアを持って生まれています。罹患率の上昇により、診断ツール、輸血、鉄キレート療法、その他の治療オプションの需要が高まっています。これらの地域の人口が増加し、認識が向上するにつれて、サラセミア管理に関連するヘルスケア サービスの需要も増加しています。この症例の急増により、遺伝子治療や幹細胞治療などのより高度な治療法の開発が促進され、市場拡大がさらに加速しています。

• 改良された輸血技術

輸血技術の進歩により、サラセミア患者の生活の質が大幅に向上し、市場成長の重要な原動力となっています。たとえば、核酸検査 (NAT) などのより安全で効率的な血液スクリーニング方法の開発により、輸血による感染のリスクが軽減され、患者の安全性が向上しました。さらに、血液型をより正確に照合する自動輸血システムにより、患者は最も適切な血液を受け取ることができるため、合併症が軽減されます。サラセミア治療における定期的な輸血の必要性が高まるにつれて、これらの進歩により、血液バンクや輸血技術などの関連サービスの需要が高まり、サラセミアケア市場が牽引されています。

機会

• 標的治療の開発

The development of targeted therapies, particularly in iron chelation and stem cell transplantation, has created significant opportunities in the thalassemia market. Iron chelation therapy, which addresses iron overload in thalassemia patients due to frequent blood transfusions, has become a cornerstone of treatment, with new, more effective chelators such as Deferasirox showing promise. In addition, stem cell transplantation offers a potential cure by restoring normal blood cell production. For instance, clinical trials involving gene therapy-based stem cell treatments are gaining momentum, with companies such as Bluebird Bio pioneering innovative solutions. These advancements not only improve patient outcomes but also attract substantial investment, boosting the market's growth potential.

• Increased Adoption of Blood Disorder Management

The increased adoption of advanced blood disorder management practices, including improved treatment regimens for thalassemia, creates a significant market opportunity. Consistent and personalized treatment plans, incorporating therapies such as iron chelation and stem cell transplantation, are enhancing patient outcomes. For instance, the use of novel drugs such as luspatercept, which stimulates red blood cell production, has shown great promise in managing thalassemia symptoms. This growing focus on efficient management not only improves the quality of life for patients but also opens doors for pharmaceutical companies and healthcare providers to offer innovative solutions. As treatment regimens become more integrated, the demand for thalassemia-related products and services continues to expand.

Restraints/Challenges

• High Treatment Costs

High treatment costs remain a significant challenge for the thalassemia market. Treatments, such as regular blood transfusions, iron chelation therapy, and emerging gene therapies, are often prohibitively expensive, especially in low-income countries. These high costs limit access to necessary medical care, causing delays in treatment and worsening patient outcomes. In regions where healthcare infrastructure is inadequate, the financial burden of continuous treatment can lead to non-compliance, further impacting the market's growth potential. The cost barriers also hinder the widespread adoption of advanced therapies, preventing many patients from receiving optimal care. As a result, this financial challenge restrains the overall growth of the thalassemia treatment market.   

• Side Effects of Current Treatments

Long-term treatments for thalassemia, particularly blood transfusions, lead to iron overload in patients. This condition, which occurs when excess iron accumulates in the body, requires additional treatment such as iron chelation therapy to prevent severe complications such as liver damage, heart failure, and endocrine dysfunction. The need for continuous monitoring and extra treatments significantly complicates the management of thalassemia. Furthermore, these additional therapies introduce further financial strain on both patients and healthcare systems. The side effects, including the high costs and potential for complications, hinder patient compliance and limit the overall effectiveness of the treatments, thereby slowing the growth of the thalassemia market.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Thalassemia Market Scope

The market is segmented on the basis of type, treatment, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Alpha-thalassemia
• Beta Thalassemia

 Treatment

• Blood Transfusions
• Iron Chelation Therapy
• Folic Acid Supplements
• Gene Therapy
• Bone Marrow Transplants

 End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Others

Thalassemia Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, type, treatment, and end user as referenced above.

The countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, U.A.E, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)

North America is expected to dominate the thalassemia market because of the growing knowledge about thalassemia and increasing government efforts to support gene therapy. Also because of the advancing of the drug pipeline which is further expected to boost the growth of the thalassemia market in the region.

Asia-Pacific is anticipated to observe significant amount of growth because of the extreme heterogeneity, an irregular frequency of thalassemia heterozygote or carrier Furthermore, government and many other organizations are working to form consciousness amongst the population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Thalassemia Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Thalassemia Market Leaders Operating in the Market Are:

• ApoPharma Inc. (Canada)
• Novartis AG (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Fresenius Kabi AG (Germany)
• Pfizer Inc. (U.S.)
• bluebird bio, Inc. (U.S.)
• Acceleron Pharma, Inc. (U.S.)
• Incyte (U.S.)
• Kiadis Pharma (Netherlands)
• Gamida Cell (Israel)
• GSK plc (U.K.)
• Ionis Pharmaceuticals, Inc. (U.S.)
• Vifor Pharma (Switzerland)
• La Jolla Pharmaceutical Company (U.S.)
• Lonza (Switzerland)
• Sangamo Therapeutics (U.S.)

Latest Developments in Thalassemia Market

• In January 2024, Agios Pharmaceuticals announced that the global Phase 3 ENERGIZE study of mitapivat in patients with non-transfusion-dependent (NTD) alpha- or beta-thalassemia successfully met its primary endpoint of hemoglobin response. In addition, both critical secondary endpoints, including changes from baseline in the FACIT-Fatigue Score and hemoglobin concentration, were found to be statistically significant, underscoring the therapeutic potential of mitapivat for NTD thalassemia patients
• In January 2024, the U.S. FDA granted approval for Casgevy, a CRISPR-based gene therapy, for its second application in treating transfusion-dependent beta-thalassemia patients aged 12 and older. This follows Casgevy's December 2023 approval for use in treating sickle cell disease. The expanded approval marks a significant milestone in advancing gene-editing therapies for blood disorders, offering a promising alternative to regular transfusions and their associated complications
• In December 2023, Editas Medicine presented new safety and efficacy data from 17 patients treated with its CRISPR-based therapy, EDIT-301 (renizgamglogene autogedtemcel), as part of the EdiTHAL trial for transfusion-dependent beta thalassemia (TDT). The trial, with six patients, highlighted positive results, demonstrating the potential of EDIT-301 to offer a transformative treatment for TDT. The findings are significant in advancing gene-editing therapies for rare blood disorders
• In November 2023, Vertex Pharmaceuticals and CRISPR Therapeutics revealed that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) granted conditional marketing authorization for Casgevy (exagamglogene autotemcel, exa-cel), a CRISPR/Cas9 gene-edited therapy. This authorization, for the treatment of transfusion-dependent beta-thalassemia (TDT), highlights the growing role of gene-editing technologies in treating inherited blood disorders and offers patients an innovative, potentially curative option for managing TDT
• In August 2022, the FDA approved Zynteglo (beti-cel), the first curative gene therapy for patients with beta-thalassemia requiring regular red blood cell transfusions. Zynteglo represents a significant advancement in the treatment of beta-thalassemia, offering a one-time gene therapy that could potentially eliminate the need for lifelong transfusions. This approval marks a transformative moment in gene therapy, providing hope for patients suffering from this debilitating genetic disorder
• In February 2022, the FDA approved PYRUKYND (mitapivat) for treating adults with pyruvate kinase (PK) deficiency, a rare and lifelong hemolytic anemia. This approval marks a significant step in addressing PK deficiency, a condition that severely impacts red blood cell production. PYRUKYND provides a novel treatment option for patients in India and globally, helping improve quality of life by reducing the severity of anemia and its associated symptoms
• In April 2021, Vertex Pharmaceuticals and CRISPR Therapeutics announced a collaboration to develop, manufacture, and commercialize CTX001, a CRISPR/Cas9-based genome-editing therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The agreement included a USD 900 million initial payment to CRISPR, with an additional USD 200 million contingent upon the first regulatory approval of CTX001. This partnership aims to bring transformative therapies to market for both SCD and TDT, offering hope for gene-based cures

SKU-34968